Explore Our Latest
Case Studies
At SeromYx, our research has advanced both vaccine and antibody therapeutic development. Our publications highlight innovative approaches such as high-dimensional immune profiling and Fc effector function assays. Explore our latest work to see the science behind our platform.
Summary: To advance SARS-CoV-2 vaccine development, SeromYx developed and GCLP-qualified a Systems Serology assay capable of reliably measuring extra-neutralizing antibody functions. This rigorously validated assay supports late-stage clinical trials and regulatory filings by expanding immune response assessment beyond neutralizing titers alone.
Summary: During the scale-up of SARS-CoV-2 monoclonal antibody production, shifts in glycosylation patterns were observed due to changes in manufacturing conditions. Using Systems Serology, SeromYx confirmed that these changes did not affect antibody function, demonstrating the platform’s value in maintaining therapeutic consistency during clinical development.
